For many patients, asthma remains uncontrolled despite current therapy. This is the asthma treatment gap, which is still a big unmet need for these patients. It is estimated that 38% of patients are considered to be GINA Step 3 of the Global Initiative for Asthma (GINA) stepwise approach to asthma treatment, and 41% of patients are considered to be at Step 4 or 5 [Adelphi Disease Specific Programme (DSP) 2018]. Despite the availability of standard-of-care asthma treatments, 35% of GINA 3 patients and over 50% of patients at GINA Step 4 and 5, respectively, remain uncontrolled (i.e. symptomatic and experience exacerbations). To help overcome this and optimise your asthma management find out about the key inflammatory mediators involved, the therapeutic targets and information from the latest Global Initiative for Asthma (GINA), global strategy for asthma management and prevention report 2019, (which should be used in conjunction with other local/national guideline recommendations).
Refresh your understanding of asthma pathophysiology and the inflammatory cascade by discovering more about potential therapeutic targets.
An updated overview to refresh your knowledge and understanding of asthma.
Learn about the stepwise approach to optimise control of moderate and severe asthma.
The epgonline.org team will be attending and reporting back from ERS 2019, held in Madrid, Spain between 28 September and 2 October providing daily blogs covering the most exciting developments in asthma and respiratory medicine.
This learning zone helps you further your knowledge around moderate and severe asthma and its management. It has been designed to support you in identifying effective approaches to optimise your management strategies, while also updating you about asthma and its treatment landscape.
Alternatively login via
Back to epgonline.org